United States News Todas as matérias

Booz Allen Hamilton (NYSE:BAH) completed its previously announced $720 million acquisition of Ultra I&C Mission Solutions, expanding its defense technology capabilities for national security customers.

H.B. Fuller (NYSE:FUL) announced that its board rejected Ancora’s unsolicited, non-binding proposal to acquire its Building Adhesives Solutions business, stating that the offer undervalues the segment.

Spruce Biosciences (NASDAQ:SPRB) announced that it completed two pre-BLA meetings with the U.S. Food and Drug Administration supporting its planned submission of a Biologics License Application for tralesinidase alfa enzyme replacement therapy in Sanfilippo Syndrome Type B.

The9 (NASDAQ:NCTY) reported unaudited net income of US$32 million for the quarter ended June 30, 2026, up more than 39% from the previous quarter, driven mainly by fair-value recognition of 9BIT tokens.

Insmed (NASDAQ:INSM) announced that Japan’s Ministry of Health, Labour and Welfare approved BRINSUPRI (brensocatib 25 mg) for adults and pediatric patients aged 12 years and older with non-cystic fibrosis bronchiectasis.

BriaCell (NASDAQ:BCTX) announced that Bria-MEL+ has passed a key genetic engineering milestone, moving the personalized whole-cell melanoma immunotherapy vaccine candidate toward potential clinical development.

Vanda Pharmaceuticals (NASDAQ:VNDA) announced that the European Commission granted orphan designation to imsidolimab for the treatment of generalized pustular psoriasis, following a positive opinion from the EMA Committee for Orphan Medicinal Products.

NAPCO Security Technologies (NASDAQ:NSSC) reported fiscal Q4 2026 revenue of $55.8 million, up 10% year-over-year, driven by growth in recurring service and equipment revenue.

Scinai Immunotherapeutics (NASDAQ:SCNI) reported first-half 2026 revenue of $949 thousand, up from $773 thousand a year earlier, driven mainly by its acquired Yavne contract development and manufacturing organization operations.

Martin Marietta (NYSE:MLM) completed its previously announced combination with Lhoist North America, a subsidiary of Lhoist Group, effective August 21, 2026.

Gogoro (NASDAQ:GGR) reported Q2 2026 revenue of $70.6 million, up 7.3% year-over-year, supported by higher hardware and other revenue.

nVent (NYSE:NVT) agreed to acquire Maverick Power for $1.75 billion, subject to customary adjustments, in a transaction aimed at expanding its power distribution and infrastructure solutions business.

PDD Holdings (NASDAQ:PDD) reported Q2 2026 revenue of RMB112.4 billion (US$16.6 billion), up 8% year-over-year, supported mainly by higher transaction services revenue.

XPENG (NYSE:XPEV) reported a second-quarter total revenue of RMB19.74 billion (US$2.91 billion) driven by strong vehicle sales.

Gilead Sciences (NASDAQ:GILD) announced that the European Commission approved Trodelvy (sacituzumab govitecan-hziy) combined with Keytruda (pembrolizumab) for adults with PD-L1-positive metastatic triple-negative breast cancer.

Precision BioSciences (NASDAQ:DTIL) announced that the first patient has been dosed in the Phase 1/2 FUNCTION-DMD trial evaluating PBGENE-DMD for Duchenne muscular dystrophy.

Comstock (NYSE:LODE) announced the completion of its sale of legacy mining, processing, and related real estate entities to Mackay Precious Metals, a subsidiary of Mackay Gold & Silver Corp., in a transaction valued at more than $45 million.

XPENG (NYSE:XPEV) announced that its robotics business has secured more than US$900 million in funding from global investors, giving the unit a post-money valuation of more than US$6.3 billion.

Ecovyst, ECVT stock, Laurie Bergman, CFO appointment, Michael Feehan, corporate leadership, executive changes, chemical industry

Robo.ai (NASDAQ:AIIO) reported net revenue of US$55.1 million for the six months ended June 30, 2026.

X Financial (NYSE:XYF) reported second-quarter 2026 total net revenue of RMB993.6 million (US$146.4 million), marking a 56.3 percent year-over-year decline.

Tanker traffic through the Strait of Hormuz remained weak over the weekend, with fewer than 20 vessels crossing the key oil route as Iran and the United States exchanged threats.

Oculis (NASDAQ:OCS) announced that the first patient has been treated in PIONEER-1, a registrational trial evaluating Privosegtor for acute optic neuritis in patients with and without multiple sclerosis.

Endeavour Silver (NYSE:EXK) announced that the blockade at its Terronera Mine in Mexico has been removed, allowing operations at the site to resume on August 24, 2026.